We are currently waiting for approval for a new indication. Is there any way to disseminate unbranded disease information concerning this new indication before approval (ex: head office emails, medical emails, banner ads, etc.)?
Please see PAAB document Pre-NOC Corporate/Editorial Communications for guidance.
792